Existing national drug surveys often ask only a few broad questions about psychedelics, while surveys drawn from psychedelic communities can miss the wider public. Rocky Mountain Poison & Drug Safety created the National Survey Investigating Hallucinogenic Trends (NSIHT) to collect detailed, substance-specific data while producing estimates for the United States adult population.

The 2025 report draws on 52,764 completed surveys, including 3,880 adults who reported psychedelic use in the previous year. It estimates that 5.3% of United States adults—about 13.9 million people—used at least one of 13 psychedelic, hallucinogenic, or dissociative substances in 2025. Psilocybin was the most common, and patterns differed by substance, age, sex, and region.

Kate M. Reynolds, MPH, will present findings on prevalence, reasons and settings for use, perceived mental and physical health effects, and side effects. The results show why national surveillance must distinguish among substances and track both regulated and unregulated use as laws and patterns of access change.

References

• Use of Psychedelic Substances in the United States, 2025: Results from the National Survey Investigating Hallucinogenic Trends (NSIHT). RMPDS Publication No. RMPDS-2026-I-01. 2026. Rocky Mountain Poison & Drug Safety, Denver Health and Hospital Authority.
• NSIHT: National Survey Investigating Hallucinogenic Trends. Rocky Mountain Poison & Drug Safety.
• Psychedelic Terminology Preference in the 2024 National Survey Investigating Hallucinogenic Trends (NSIHT). Lyons FE, Rockhill KM, Fox EJ, et al. 2026. DOI: 10.1080/02791072.2026.2644863. Journal of Psychoactive Drugs.

Oregon’s psilocybin program allows adults to receive mushroom-derived psilocybin at licensed service centers under the supervision of licensed facilitators. It differs from clinical trials in important ways: clients do not need a diagnosis or referral, services occur in community settings, and clinical treatment is generally outside the facilitator’s scope.

The Open Psychedelic Evaluation Nexus followed 346 clients at 24 of Oregon’s 26 active service centers, with confidential assessments before their session and at one week, one month, and three months afterward. Four participants, or 1.2%, experienced behavioral reactions requiring medical attention. At one month, 92.2% reported that they had benefited from the experience; at three months, participants reported lower levels of depression, anxiety, and post-traumatic stress symptoms, along with greater mental well-being and life satisfaction.

Jason B. Luoma, PhD, will present these findings and their limits. The longitudinal outcome and safety results come from the 346-person prospective cohort; the paper also compares that cohort with Oregon Health Authority administrative data for all service recipients during the overlapping period to assess representativeness. The study is observational and has no control group, but it offers an early view of real-world safety, outcomes, informed consent, and the need for longer-term monitoring.

References

• Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services. Korthuis PT, Cook RR, Gregoire D, et al. 2026;9(8):e2630608. DOI: 10.1001/jamanetworkopen.2026.30608. JAMA Network Open.
• Oregon Psilocybin Services Data and Reporting. Oregon Health Authority.

Governor Michelle Lujan Grisham signed Senate Bill 219, the Medical Psilocybin Act, on April 7, 2025. The law created a program within the New Mexico Department of Health for qualified patients with treatment-resistant depression, post-traumatic stress disorder, substance use disorders, and end-of-life anxiety or depression.

The law authorizes natural psilocybin in approved settings under clinical supervision, creates a Medical Psilocybin Advisory Board, and establishes separate funds for treatment access and research. It also directs the Department of Health to collect data, evaluate the program, and publish annual assessments.

Denali Wilson, New Mexico State Director of Strategic Support at the Healing Advocacy Fund, will explain the model as the Department develops rules for producers, laboratories, clinicians, approved settings, treatment protocols, and safety. The statute requires implementation by December 31, 2027; the Department’s current public goal is to enroll the first patients by the end of December 2026, with medical use and supervised dosing beginning once the rules and regulations are complete and in effect. The session will examine how New Mexico’s medical framework differs from the broader adult-access systems in Oregon and Colorado.

References

• Medical Psilocybin Act. Senate Bill 219, Chapter 73, signed April 7, 2025. New Mexico Legislature.
• Medical Psilocybin Program. New Mexico Department of Health.
• Medical Psilocybin Program Frequently Asked Questions. New Mexico Department of Health.
• White Paper on Psilocybin. Updated September 3, 2024. New Mexico Department of Health.

What if psychedelic healing could do more than help young people recover from trauma? What if it could expand the boundaries of who they believe they can become? Harry Grammer, PhD, and Ariana Zepeda, LCSW, of New Earth share a powerful journey from the concrete walls of youth incarceration to psychedelic-assisted therapy, the rainforests of Costa Rica and Ecuador, and an emerging vision for a new generation of global service leaders. Drawing from New Earth’s work with formerly incarcerated and at-risk youth ages 13–25, they explore a model where psychedelics open the window, nature becomes the doorway, the world becomes the classroom, and service becomes the purpose. The presentation will introduce New Earth’s developing Community Care Clinic in Los Angeles and the vision for Nueva Tierra in Ecuador to help young people move beyond the boundaries of trauma, neighborhoods, and systems to discover their place, purpose, and capacity to serve in a much larger world.

W. Bryan Hubbard, Chief Executive Officer of Americans for Ibogaine, and Maj. Gen. Glenn H. Curtis (Ret.), an Americans for Ibogaine Ambassador and founder of Awaken Warriors, will discuss the coalition forming around the clinical development of ibogaine and related psychedelic medicines in the United States. Their perspectives bring together policy strategy, military and veteran advocacy, tribal leadership, and lived experience.

The session traces recent state legislation and research programs, Executive Order 14401, and the Advanced Research Projects Agency for Health’s ASCENT-IBO initiative. ASCENT-IBO calls for early-stage clinical trials of ibogaine for opioid use disorder and coordination among researchers, clinicians, government, and other partners. The speakers will consider how coalitions can secure public investment, build durable research pathways, and maintain accountability as the evidence base develops.

Ibogaine remains a Schedule I controlled substance and is not approved for medical use in the United States. The conversation will address what responsible progress requires: rigorous trials, appropriate clinical safeguards, community participation, and transparent oversight before broader access is considered.

References

• Ibogaine Legislation: State-by-State Tracker. Americans for Ibogaine.
• Accelerating Medical Treatments for Serious Mental Illness. Executive Order 14401, April 18, 2026. The White House.
• ASCENT-IBO: Accelerating Safe Clinical Evaluation of Novel Treatments: Ibogaine for Better Outcomes in Opioid Use Disorder. Advanced Research Projects Agency for Health.

Over the last five years, a bipartisan political coalition has accomplished a dazzling streak of cultural and policy victories that seemed impossible as recently as ten years ago.

While united by a desire to increase safe and effective treatment options for serious mental health and neurological disorders, tensions have emerged as communities with dramatically different belief systems and values attempt to collaborate.

What are the unique forces that have held an unlikely coalition together thus far, and can they withstand the energy that may soon be released as idealized dreams convert into complex realities?

Ibogaine, once obscure not only in American popular culture but even within its psychedelic community, has stepped into the limelight.

While much has been made of what ibogaine might do for North Americans and Europeans struggling with addiction, traumatic brain injury, and other serious illnesses, much less attention has been paid to the living communities from which it originates.

The history of the Gabon nation and its relationship with the United States, the many ethnic communities and tribes that inhabit its lands, and the Bwiti religious practices and other traditional uses of tabernanthe iboga, and the day-to-day lives of Gabonese citizens are rich cultural stories that are still very much still being written.

How might the newfound American and global passion for ibogaine affect this already-complex cultural, ecological, and economic landscape, and what are the futures that Gabonese communities hope will emerge from this unexpected historical moment?

Long before mescaline arrived in the Victorian-era avant garde, Andean communities developed relationships with Huachuma—also known as San Pedro—that were inseparable from place, ceremony, collective life, and systems of knowledge carried across generations. Those living traditions continue, but are under pressure from tourism, international trade, ecological degradation, and extraction.

Representatives of Colectivo Huachuma will trace the history and present condition of Huachuma in the Quechua lands and beyond, and share a message from a new association that represents more than 200 maestros curanderos in northern Peru.

The session asks what stewardship requires when a plant, a landscape, a living healing tradition, and a local economy are all at stake. What philosophies and practices can preserve and strengthen traditional biocultures in a rapidly changing world?

References

• New statements from the Maestros Curanderos of North Peru. July 15, 2026. Huachuma Collective.
• Huachuma Collective: Biocultural conservation in the Andes. Official website. Huachuma Collective.

As the 19th Horizons conference comes to an end, speakers from across its many included disciplines will offer their parting thoughts, hopes, dreams, and questions after three long days of learning, connection, and community.